Announcement on Amending the Articles of Association of the Company
Release time:
2020-08-05
证券代码：600668 证券简称：尖峰集团 编号：临2019-014
债券简称：13尖峰02 债券代码：122344
浙江尖峰集团股份有限公司
关于修订公司《章程》的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。
根据《中华人民共和国公司法》（2018年修订）、中国证监会《关于修改〈上市公司章程指引〉的决定》（证监会公告[2019]10号）和《上海证券交易所股票上市规则》（2018年修订）等相关规定及公司运行情况，拟对公司《章程》部分条款进行修订。
2019年4月26日，公司召开了第十届董事会第10次会议，经审议与表决，以9票同意、0票反对、0票弃权，审议通过了公司《章程》修订案。
具体修订内容对照如下：
|
序列 |
修改前 |
修改后 |
|
1 |
第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 |
第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共和国证券法》（以下简称《证券法》）、《中国共产党章程》（以下简称《党章》）和其他有关规定，制订本章程。 |
|
2 |
第二十三条 公司在下列情况下，可以依照法律、行政法规、部门规章和本章程的规定，收购本公司的股份：
（一）减少公司注册资本；
（二）与持有本公司股票的其他公司合并；
（三）将股份奖励给本公司职工；
（四）股东因对股东大会作出的公司合并、分立决议持异议，要求公司收购其股份的。
除上述情形外，公司不进行买卖本公司股份的活动。 |
第二十三条 公司在下列情况下，可以依照法律、行政法规、部门规章和本章程的规定，收购本公司的股份：
（一）减少公司注册资本；
（二）与持有本公司股份的其他公司合并；
（三）将股份用于员工持股计划或者股权激励；
（四）股东因对股东大会作出的公司合并、分立决议持异议，要求公司收购其股份；
（五）将股份用于转换上市公司发行的可转化为股票的公司债券；
（六）上市公司为维护公司价值及股东权益所必需。
除上述情形外，公司不进行收购本公司股份的活动。 |
|
3 |
第二十四条 公司收购本公司股份，可以选择下列方式之一进行：
（一）证券交易所集中竞价交易方式；
（二）要约方式；
（三）中国证监会认可的其他方式。 |
第二十四条 公司收购本公司股份，可以选择下列方式之一进行：
（一）证券交易所集中竞价交易方式；
（二）要约方式；
（三）中国证监会认可的其他方式。
公司因本章程第二十三条第一款第（三）项、第（五）项、第（六）项规定的情形收购本公司股份的，应当通过公开的集中交易方式进行。 |
|
4 |
第二十五条 公司因本章程第二十三条第（一）项至第（三）项的原因收购本公司股份的，应当经股东大会决议。公司依照第二十三条规定收购本公司股份后，属于第（一）项情形的，应当自收购之日起10日内注销；属于第（二）项、第（四）项情形的，应当在6个月内转让或者注销。
公司依照第二十三条第（三）项规定收购的本公司股份，将不超过本公司已发行股份总额的5%；用于收购的资金应当从公司的税后利润中支出；所收购的股份应当1年内转让给职工。 |
第二十五条 公司因本章程第二十三条第一款第（一）项、第（二）项规定的情形收购本公司股份的，应当经股东大会决议；公司因本章程第二十三条第一款第（三）项、第（五）项、第（六）项规定的情形收购本公司股份的，可以依照本章程的规定或者股东大会的授权，经三分之二以上董事出席的董事会会议决议。
公司依照本章程第二十三条第一款规定收购本公司股份后，属于第（一）项情形的，应当自收购之日起 10 日内注销；属于第（二）项、第（四）项情形的，应当在6 个月内转让或者注销；属于第（三）项、第（五）项、第（六）项情形的，公司合计持有的本公司股份数不得超过本公司已发行股份总额的 10%，并应当在 3 年内转让或者注销。 |
|
5 |
第四十四条 本公司召开股东大会的地点为：公司住所地。
股东大会将设置会场，以现场会议形式召开。公司还将视情况提供网络方式为股东参加股东大会提供便利。股东通过上述方式参加股东大会的，视为出席。 |
第四十四条 本公司召开股东大会的地点为：公司住所地。
股东大会将设置会场，以现场会议形式召开。公司还将提供网络投票的方式为股东参加股东大会提供便利。股东通过上述方式参加股东大会的，视为出席。
发出股东大会通知后，无正当理由，股东大会现场会议召开地点不得变更。确需变更的，召集人应当在现场会议召开日前至少 2 个工作日公告并说明原因。 |
|
6 |
第七十七条 下列事项由股东大会以特别决议通过：
（一）公司增加或者减少注册资本；
（二）公司的分立、合并、解散和清算；
（三）本章程的修改；
（四）公司在一年内购买、出售重大资产或者担保金额超过公司最近一期经审计总资产30%的；
（五）股权激励计划；
（六）修改公司现金分红政策；
（七）法律、行政法规或本章程规定的，以及股东大会以普通决议认定会对公司产生重大影响的、需要以特别决议通过的其他事项。 |
第七十七条 下列事项由股东大会以特别决议通过：
（一）公司增加或者减少注册资本；
（二）公司的分立、合并、解散和清算；
（三）本章程的修改；
（四）公司在一年内购买、出售重大资产或者担保金额超过公司最近一期经审计总资产 30%的；
（五）股权激励计划；
（六）修改公司现金分红政策；
（七）因本章程第二十三条第（一）、（二）项规定的情形收购本公司股份；
（八）法律、行政法规或本章程规定的，以及股东大会以普通决议认定会对公司产生重大影响的、需要以特别决议通过的其他事项。 |
|
7 |
第七十八条 股东（包括股东代理人）以其所代表的有表决权的股份数额行使表决权，每一股份享有一票表决权。
公司持有的本公司股份没有表决权，且该部分股份不计入出席股东大会有表决权的股份总数。
董事会、独立董事和符合相关规定条件的股东可以征集股东投票权。 |
第七十八条 股东（包括股东代理人）以其所代表的有表决权的股份数额行使表决权，每一股份享有一票表决权。
股东大会审议影响中小投资者利益的重大事项时，对中小投资者表决应当单独计票。单独计票结果应当及时公开披露。
公司持有的本公司股份没有表决权，且该部分股份不计入出席股东大会有表决权的股份总数。
董事会、独立董事和符合相关规定条件的股东可以征集股东投票权。征集股东投票权应当向被征集人充分披露具体投票意向等信息。禁止以有偿或者变相有偿的方式征集股东投票权。公司不得对征集投票权提出最低持股比例限制。 |
|
8 |
第八十条 公司应在保证股东大会合法、有效的前提下，通过各种方式和途径，包括提供网络形式的投票平台等现代信息技术手段，为股东参加股东大会提供便利。 |
第八十条 公司应在保证股东大会合法、有效的前提下，通过各种方式和途径，优先提供网络形式的投票平台等现代信息技术手段，为股东参加股东大会提供便利。 |
|
9 |
新增第五章“党组织”，其后章节顺延。 |
第九十五条 根据《党章》规定，公司设立党的组织，开展党的活动。公司党组织是公司法人治理结构的有机组成部分，发挥领导核心和政治核心作用，把方向、管大局、保落实。
第九十六条 公司根据《公司法》和《章程》的规定，设立公司党委、公司纪委和各基层党组织，公司应当为各级党组织及其纪委的活动提供必要的条件。
第九十七条 公司党组织书记和董事长原则上由一人担任。符合条件的党组织领导班子成员可通过法定程序进入董事会、监事会、经理层，董事会、监事会、经理层成员中符合条件的党员可依照有关规定和程序进入公司党委、纪委。 More information Yunnan peak through the safety standard secondary acceptance On March 21, Yunnan Jianfeng Cement Company successfully passed the evaluation and acceptance of secondary enterprises for safety production standardization. On the same day, a review team composed of leaders of the Yunnan Provincial Work Safety Supervision Bureau and relevant experts reviewed the implementation of the establishment of Yunnan Jianfeng safety production standardization secondary enterprises. According to the 13 elements involved in the "Standard for Assessment and Rating of Safety Production Standardization in Cement Enterprises", the review team conducted strict assessment and scoring item by item through grouping to check the site and review the data, and finally determined that Yunnan Peak passed the standard acceptance of safety standardization secondary enterprises. Yunnan Jianfeng has always attached great importance to safety production. After passing the three-level safety standard enterprise review in 2015, in order to raise the level of enterprise safety management to a new level, in 2016, it began to create secondary safety standardization. Over the past year, Yunnan Jianfeng has insisted on taking the creation of secondary safety standards as the top priority of production and operation management, and has formulated an implementation plan for production safety standardization in accordance with the requirements of national standardization norms. the content covers production safety responsibility system, education and training, safety inspection, safety facilities management and other safety production management standards, systems and post safety operation procedures, while further strengthening daily safety inspection and regularly organizing emergency plan drills, strengthen the investigation and rectification of potential safety hazards and the supervision of important hazard sources, and further consolidate the foundation of enterprise safety production management. After the review, Zhou Jiping, general manager of Yunnan Jianfeng, said that Yunnan Jianfeng will take this standard as a new starting point. On the basis of consolidating the accident-free achievements in production safety for two consecutive years, it will conscientiously implement the main responsibility of production safety and cultivate 2020 07-30 Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory News from our newspaper On February 28, the 10th meeting of the 9th Board of Directors of the Group Company reviewed and approved the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman of the Board of Directors." On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biological formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through the cooperation with Yale University, we have obtained the patent authorization and commercial development license of the new anti-cancer chemical drug trasatabine (trokacitabine)(which has obtained the national new drug clinical approval in August 2016), the anti-hepatitis B chemical drug Crevudine (Clevudine). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biology, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly built by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has production workshops for multiple dosage forms such as percolation, tincture, solid preparations and liquid preparations. 2020 07-31 Peak health marketing and a new "play" Building a New System, Flattening Management, Spike Health Marketing, New "Fit" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original division model, combines all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health) 2020 07-31 Peak health marketing and a new "play" Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health) 2020 07-31 Accident-free factory creation enters "second season" At the beginning of the new year, a major "highlight" of the company's safety and environmental protection management in recent years-the "second quarter" of the establishment of a safety and environmental protection accident-free factory has also begun. Safety and environmental protection accident-free factory creation activities are an important measure for the company to improve the level of on-site management. The first phase of the activity will start on January 1, 2014 and end at the end of 2016 for a period of three years. Since the launch of the activity, all subordinate enterprises of the company have actively organized publicity and training related to safety and environmental protection, strengthened the awareness of safety and environmental protection of all employees, improved the management and operation level of safety and environmental protection; increased investment in safety and environmental protection facilities and equipment; strengthened safety and environmental protection inspection and self-examination and correction of hidden dangers, and timely organized rectification of hidden dangers; strictly assessed the units and relevant responsible persons of the accident, And the accident situation in the group, in order to arouse vigilance and avoid similar accidents. In the past three years, the company's subsidiaries have achieved remarkable results in standardization, safety, and clean operation. Safety and environmental protection accidents have dropped significantly, and no major accidents have occurred, which has effectively promoted the company's safe and civilized production construction. In the 2016 safety and environmental protection accident-free factory establishment assessment conducted a few days ago, a total of 6 units met the accident-free factory standard, of which Yunnan Jianfeng, Jianfeng International Trade and Pharmaceutical Department met the standard for the second consecutive year, and Daye Jianfeng, Qiubin Factory and Cable Company met the standard in the first year. In order to sum up experience and further improve the level of safety and environmental protection management, the Group decided to continue to open 2020 07-31 What will the Chinese Medicine Act bring us? At the 25th meeting of the Standing Committee of the 12th National People's Congress in December 2016, the the People's Republic of China Chinese Medicine Law (hereinafter referred to as the Chinese Medicine Law) was deliberated and passed, which will come into effect on July 1 this year. As the first comprehensive law that comprehensively and systematically embodies the characteristics of traditional Chinese medicine, the Law of traditional Chinese Medicine clearly stipulates the service of traditional Chinese medicine, the protection and development of traditional Chinese medicine, the training of talents of traditional Chinese medicine, and the scientific research of traditional Chinese medicine. With the change of people's health concept and the continuous innovation of medical mode in recent years, the role of traditional Chinese medicine in health is becoming more and more important. The promulgation of the "Traditional Chinese Medicine Law" has made the development of Chinese medicine more law-based, and it is bound to bring changes to domestic pharmaceutical companies. So, the peak of the pharmaceutical, health products companies will look at the "Chinese Medicine Law", and will have how to deal with it? A few days ago, the reporter interviewed the pharmaceutical companies and peak health technology companies related to the person in charge. What will the Chinese Medicine Act bring us? Reporter: As the general manager of Peak Pharmaceutical, what do you think of the Chinese Medicine Law? Huang Jinlong (Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company): the Law of traditional Chinese Medicine defines the important position and development policy of traditional Chinese medicine. The state encourages traditional Chinese medicine and western medicine to learn from each other, complement each other, coordinate development, give full play to their respective advantages, and promote the integration of traditional Chinese and western medicine. Traditional Chinese medicine is a huge knowledge system, reflecting the Chinese nation's understanding of life, health and disease. It is precisely because of the distinctive characteristics of Chinese medicine that the Law of Chinese Medicine is used in Chinese medicine clinics, Chinese medicine physicians and doctors. 2020 07-31 Contact Us 
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China 
Tel: +86-579-82326868 
Fax : +86-579-82324666 
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
|
